Coexistence of bone and vascular disturbances in patients with endogenous glucocorticoid excess

Chieko Yano, Maki Yokomoto-Umakoshi *, Masamichi Fujita, Hironobu Umakoshi, Seiichi Yano, Norifusa Iwashashi, Shunsuke Katsuhara, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Yayoi Matsuda, Ryuichi Sakamoto, Yoshihiro Ogawa *

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

**Article Info**

**Keywords:**
Glucocorticoid
Bone
Vascular
Osteoporosis
Atherosclerosis
Endogenous Cushings’s syndrome

**Abstract**

**Purpose:** Bone and vascular diseases are considered to share pathogenic mechanisms. Excess glucocorticoids, key regulators of cardiovascular and metabolic homeostasis, may promote both diseases simultaneously. We used endogenous Cushings’s syndrome (CS) to investigate whether glucocorticoid excess underlies coexisting bone and vascular diseases.

**Methods:** We included 194 patients with adrenal tumors (ATs): autonomous cortisol secretion (ACS, n = 97) and non-functional AT (n = 97). ACS was further classified into overt CS (n = 17) and subclinical CS (SCS, n = 80). Arterial stiffness was defined as a brachial-ankle pulse wave velocity (baPWV) ≥ 1800 cm/s.

**Results:** Patients with ACS had higher coexistence rates of vertebral fracture and arterial stiffness (23 % vs. 2 %; p < 0.001) and vertebral fracture and abdominal aortic calcification (22 % vs. 1 %; p < 0.001) than those with non-functional AT. In patients with ACS, baPWV was negatively correlated with trabecular bone score (TBS, r = −0.33; p = 0.002), but not with bone mineral density, and vertebral fracture was associated with arterial stiffness in the logistic regression analysis. In the multivariate analysis of variance, the degree of cortisol excess (defined as CS, SCS, and non-functional AT) determined the correlation between TBS and baPWV (partial η² = 0.07; p < 0.001). In the analysis of covariance, patients with coexisting vertebral fracture and arterial stiffness had higher levels of serum cortisol after the 1-mg dexamethasone suppression test than those without.

**Conclusion:** In endogenous glucocorticoid excess, bone and vascular diseases frequently coexisted, and deteriorated bone quality, not bone loss, was related to arterial stiffness. Thus, glucocorticoid excess may perturb the bone-vascular axis.

1. Introduction

Long-term exposure to glucocorticoids due to endogenous glucocorticoid excess in Cushings’s syndrome (CS) or exogenous glucocorticoid administration is associated with various cardiometabolic complications (Newell-Price et al., 2006). Glucocorticoid-induced osteoporosis results in decreased bone strength and an increased risk of fracture, which greatly reduces the quality of life (Hermus et al., 1995; Tauchmanova et al., 2006; Chiiodini et al., 2009). Further, patients with endogenous glucocorticoid excess have a higher risk of death compared to the general population, mainly due to cardiovascular diseases (van Haalen et al., 2015), and often develop atherosclerosis (Faggiano et al., 2003; Neary et al., 2013).

Bone and vascular diseases often coexist, both being common age-related diseases (Tankó et al., 2005; Lewis et al., 2019; Raisi-Estapharagh et al., 2021). They share risk factors and pathogenic mechanisms, which are known as the “bone-vascular axis” (Thompson and Towler, 2012). Dysmetabolic states, such as diabetes mellitus and hyperlipidemia, perturb the bone-vascular axis, thus allowing both diseases to develop simultaneously (Thompson and Towler, 2012; Wagenknecht et al., 2016). Previous experimental studies suggest that excess glucocorticoids, key regulators of cardiovascular and metabolic homeostasis, also perturb the bone-vascular axis. Particularly, exogenous glucocorticoid administrations cause vascular calcification by promoting...
osteogenic differentiation of vascular cells (Kirton et al., 2006; Mori et al., 1999). However, whether glucocorticoid excess promotes the coexistence of bone and vascular diseases in humans remains unclear.

Since endogenous CS occurs rarely, much of our knowledge about glucocorticoid-induced osteoporosis and atherosclerosis have been from studies of patients treated with exogenous glucocorticoids (Toth and Grossman, 2013). These studies are limited by the fact that patients treated with glucocorticoids usually have primary disease(s) that may affect bone and vascular conditions. In this regard, endogenous CS would provide a better understanding of the direct effect of glucocorticoid excess on bone and vascular pathologies. The aim of the present study was to investigate how endogenous glucocorticoid excess is involved in the coexistence of bone and vascular diseases.

2. Materials and methods

2.1. Study design

This was a retrospective cross-sectional study conducted at the Kyushu University Hospital, a referral center in Japan. The study protocol was approved by the Institutional Ethics Committee (No. 21025-00). The study was performed in accordance with the guidelines for clinical studies published by the Ministry of Health and Labour, Japan. Informed consent was obtained from all patients upon hospital admission.

2.2. Patients

We enrolled 613 consecutive patients with adrenal tumors (ATs), who were admitted to our endocrine unit between January 2013 and September 2021 (Fig. 1). Patients with primary aldosteronism (n = 265), pheochromocytoma (n = 120), adrenal cortical carcinoma (n = 3), or adrenal metastasis (n = 1) were excluded. Patients with conditions that are known to affect bone or vascular metabolism (e.g., glucocorticoid treatment, primary hyperparathyroidism, and active malignancies) were excluded (n = 16). The patients who were not assessed using the 1-mg dexamethasone suppression test (1 mg-DST; n = 11) or with those with an incomplete assessment of bone and vascular parameters (n = 3) were excluded. Finally, we included 194 patients who were examined for both bone and vascular parameters, of whom 97 had autonomous cortisol secretion (ACS) and 97 had non-functional AT as a control. None of patients included in this study were treated with antiresorptive drugs (bisphosphonates, denosumab) and osteoanabolic drug (teriparatide). None of the patients in this study were also supplemented with calcium or vitamin D as medical treatment, but we were unable to ascertain whether patients were taking them personally. At least one of the following bone parameters was examined: vertebral fracture, bone mineral densities (BMDs) at the lumbar spine and femoral neck, and...
trabecular bone score (TBS). Vascular parameters were examined for brachial-ankle pulse wave velocity (baPWV), abdominal aortic calcification, or both, which are the standard measures for assessing atherosclerosis (Townsend et al., 2015; Szulc, 2016). Patients with ACS and non-functional AT were diagnosed based on a serum cortisol level after midnight serum cortisol at 2300 h, morning plasma dehydroepiandrosterone sulfate (DHEAS) and 25-hydroxyvitamin D levels were measured, as described previously (Yokomoto-Umakoshi et al., 2020c). Dehydroepiandrosterone sulfate (DHEAS) and 25-hydroxyvitamin D levels were measured using electrochemiluminescence and chemiluminescent enzyme immunoassays, respectively.

2.7. Statistical analysis

The clinical characteristics between patients with ACS and those with non-functional AT were compared using the Mann-Whitney U or Fischer's exact test, as appropriate. In patients with ACS, the correlation between bone and vascular parameters was examined using Spearman's test and after adjusting for possible confounders, we examined the association using logistic regression analysis. Further, clinical characteristics among patients with CS, SCS, and non-functional AT were compared using the Fischer's exact or Kruskal-Wallis test, as appropriate, with post-hoc Bonferroni correction. Multivariate analysis of variance (MANOVA) was performed to evaluate whether cortisol excess was a determinant of the correlated bone and vascular parameters. The analysis of covariance (ANCOVA) was performed to evaluate the differences in post-DST cortisol between patients with and without coexisting bone and vascular diseases. Possible confounders included age, gender, BMI, alcohol intake, smoking status, and the presence of diabetes mellitus, hypertension, and hyperlipidemia, all of which affected bone and vascular diseases (Ensrud and Crandall, 2017; Herrington et al., 2016). Continuous variables with skewed distributions were log-transformed, as appropriate. All tests were two-tailed, and \( p < 0.05 \) was set as statistical significance. Statistical analyses were performed using R software (version 4.0.3) (R Core Team, 2013).

3. Results

3.1. Comparison of clinical characteristics between patients with ACS and those with non-functional AT

Clinical characteristics between patients with ACS (\( n = 97 \)) and those with non-functional AT (\( n = 97 \)) were compared (Table 1). Patients with ACS had higher levels of basal serum cortisol, midnight serum cortisol, 24 h urinary free cortisol, and post-DST cortisol. Further, they had higher frequencies of diabetes mellitus, hypertension, and hyperlipidemia and lower levels of ACTH and DHEAS. Regarding bone parameters, patients with ACS had a higher frequency of vertebral fracture, lower BMD Z score at the lumbar spine, femoral neck and TBS; and a higher intact-PTH level and urinary calcium-to-creatinine ratio than those with non-functional AT. Regarding vascular parameters, patients with ACS had higher frequencies of arterial stiffness and abdominal aortic calcification than those with non-functional AT. Furthermore, patients with ACS had higher rates of coexistence of vertebral fracture and arterial stiffness (23 %, 18/76 vs. 2 %, 2/83; \( p < 0.001 \)) and vertebral fracture and abdominal aortic calcification (22 %, 17/77 vs. 1 %, 1/84; \( p < 0.001 \)) than those with non-functional AT. There was no significant difference in age, gender, menopausal status, BMI, alcohol intake, smoking status, eGFR, serum calcium, 25-hydroxyvitamin D, TRACP5b, or BAP level between the two groups.

3.2. Correlation between bone and vascular parameters in patients with ACS

We examined the correlation between bone parameters and baPWV in patients with ACS. In these analyses, the TBS, BMD, baPWV, and the levels of BAP, TRACP5b, and intact-PTH were log-transformed. TBS was

2.3. Data collection for baseline characteristics

Information regarding alcohol intake (\( < \) or \( > 3 \) units/day), smoking status (past or current), and menopause status was obtained using an interviewer-assisted questionnaire. Diabetes mellitus was diagnosed when the patient had glycosylated hemoglobin \( \geq 6.5 \% \), a fasting glucose level \( \geq 126 \text{ mg/dL} \), or a history of antidiabetic medication. Hypertension was diagnosed when the patient had a history of antihypertensive medication or a 24 h blood pressure \( > 140/90 \text{ mmHg} \). Hyperlipidemia was diagnosed when the patient had a serum low-density lipoprotein-cholesterol level \( > 140 \text{ mg/dL} \) or a history of lipid-lowering medication.

2.4. Evaluation of bone parameters

Lateral radiographs of the thoracic and lumbar spines were examined to diagnose vertebral fractures, a hallmark of osteoporosis (Kanis, 2002), using the Genant semi-quantitative visual assessment (Genant et al., 1993), as described previously (Yokomoto-Umakoshi et al., 2020b). “Severe vertebral fracture” was diagnosed when the patient had multiple vertebral fractures or a grade-3 vertebral fracture (Soen et al., 2013). Two trained investigators, who were blinded to each other’s assessment, obtained the diagnoses, with an interrater reliability of 0.80. A third investigator resolved the disagreements. None of the patients had a history of severe trauma. BMDs at the lumbar spine (L1-L4) and femoral neck were obtained by dual-energy X-ray absorptiometry using the Discovery A system (Hologic, Waltham, MA, US), with coefficients of variation of 0.93 % and 1.74 %, respectively. TBS was retrospectively analyzed in a blinded manner from BMD at the lumbar spine using TBS iNsight software, version 3.0.3.0 (Medimaps, France), with a coefficient of variation of 1.12 %. All patients evaluated for TBS were older than 20 years and had a body mass index (BMI) \( \leq 35 \text{ kg/m}^2 \).

2.5. Evaluation of vascular parameters

The baPWV was measured in the supine position after 15 min of rest using an automatic waveform analyzer (Omron Colin Co., Ltd., Komaki, Japan). Arterial stiffness was diagnosed when the patient had a baPWV \( \geq 1800 \text{ cm/s} \) (Munakata, 2014). Abdominal aortic calcification was diagnosed using the semi-quantitative method by Kauppila et al. (Kauppila et al., 1997) and lateral radiographs of the lumbar spine as described previously (Yokomoto-Umakoshi et al., 2020b). Abdominal aortic calcification was diagnosed when the patient scored \( \geq 3 \) (Bagger et al., 2006). Two investigators blinded to each other’s assessment obtained the diagnoses, with an interrater reliability of 0.93. A third investigator resolved the disagreements.

2.6. Biochemical measurements and assay methods

We collected basal serum cortisol at 0800 h (reference range, 6.2–18.0 \( \mu \text{g/dL} \)), midnight serum cortisol at 2300 h, morning plasma adrenocorticotropic hormone (ACTH), 24 h urinary free cortisol, and post-DST cortisol. For post-DST cortisol, 1 mg of dexamethasone had been administered at 2300 h the day before the collection. Their reference ranges and assay methods have been described previously (Yokomoto-Umakoshi et al., 2020c). The estimated glomerular filtration rate (eGFR), serum calcium level, intact-parathyroid hormone (PTH) level, urinary calcium-to-creatinine ratio, tartrate-resistant acid phosphatase-5b (TRACP5-b) level, and bone-alkaline phosphatase (BAP) level were measured, as described previously (Yokomoto-Umakoshi et al., 2020c).
Table 1 (continued)

| Variables | ACS (n = 97) | Non-functional AT (n = 97) | p-Value |
|-----------|-------------|---------------------------|---------|
| 25-hydroxyvitamin D, ng/mL | 13.7 | 14.3 [10.5, 18.5] | 0.331 |
| TRACP-5b, μU/mL | 358 | 323 [251, 433] | 0.514 |
| BAP, pg/L | 12.3 | 12.5 [9.9, 15.9] | 0.734 |
| Vascular parameters | | | |
| baPWV, cm/s | 1675 [1451, 1891] | 1541 [1365, 1707] | 0.007* |
| Arterial stiffness, % | 37% [36/95] | 21% [20/95] | 0.017* |
| Abdominal aortic calcification, % | 32% [25/77] | 15% [13/84] | 0.015* |
| Coexistence rates of bone and vascular diseases | | | |
| Vertebral fracture and arterial stiffness, % | 23% [18/76] | 2% [2/83] | <0.001* |
| Vertebral fracture and abdominal aortic calcification, % | 22% [17/77] | 1% [1/84] | <0.001* |

Table 1 Comparison of clinical characteristics between patients with ACS and those with non-functional AT.

| Variables | ACS (n = 97) | Non-functional AT (n = 97) | p-Value |
|-----------|-------------|---------------------------|---------|
| Baseline parameters | | | |
| Age, y | 62.0 | 58.0 [51.0, 67.0] | 0.840 |
| Gender, female, % | 61% | 53% [52/97] | 0.309 |
| Postmenopausal female, % | 58% | 73% [38/97] | 0.116 |
| BMI, kg/m² | 24.1 | 21.4 [21.8, 27.1] | 0.465 |
| Alcohol intake, % | 48% | 45% [44/97] | 0.772 |
| Smoking status, % | 53% | 44% [43/97] | 0.248 |
| Basal serum cortisol, μg/dL | 14.6 | 12.7 [9.1, 15.9] | 0.024* |
| ACTH, pg/mL | 6.8 [1.5, 15.7] | 24.0 [16.6, 37.1] | <0.001* |
| Midnight serum cortisol, μg/dL | 6.0 [4.5, 11.5] | 2.9 [2.0, 37.1] | <0.001* |
| Post-DST cortisol, μg/dL | 4.0 [2.5, 12.3] | 1.1 [0.8, 37.1] | <0.001* |
| 24 h urinary free cortisol, μg/dL | 59.4 [36.7, 90.3] | 43.7 [31.8, 59.8] | 0.003* |
| DHEAS, μg/dL | 38.0 [15.7, 65.5] | 92.0 [61.5, 142.5] | <0.001* |
| eGFR, ml/min/1.73m² | 81.0 [65.4, 94.9] | 81.0 [71.0, 93.0] | 0.998 |
| Diabetes mellitus, % | 44% [43/97] | 22% [22/97] | 0.002* |
| Hypertension, % | 71% [69/96] | 52% [50/96] | 0.007* |
| Hyperlipidemia, % | 56% [55/97] | 36% [35/97] | 0.006* |
| Bone parameters | | | |
| Vertebral fracture, % | 49% [38/77] | 8% [7/84] | <0.001* |
| Severe vertebral fracture, % | 16% [13/77] | 2% [2/84] | 0.002* |
| BMD at lumbar spine, g/cm² | 0.87 | 0.88 [0.80, 0.90] | 0.065 |
| BMD at lumbar spine Z score | 0.2 | 0.3 [0.1–0.6] | 0.043* |
| BMD at femoral neck, g/cm² | 0.62 | 0.65 [0.60, 0.76] | 0.010* |
| BMD at femoral neck Z score | 0.3 | 0.5 [0.3, 0.8] | 0.025* |
| TBS | 1.34 | 1.37 [1.31, 1.42] | 0.026* |
| Serum calcium, mg/dL | 9.3 [9.1, 9.5] | 9.3 [9.1, 9.5] | 0.312 |
| Intact-PTH, pg/mL | 53.8 | 43.8 [34.5, 54.7] | 0.006* |
| Urinary calcium-to-creatinine ratio | 0.17 | 0.13 [0.08, 0.20] | 0.049* |

Data are expressed as median [interquartile range] or percentage (number of patients). Severe vertebral fracture was defined as multiple vertebral fractures or a grade 3 vertebral fracture. Arterial stiffness was defined as a baPWV ≥1800 cm/s. Abbreviations: ACS, autonomous cortisol secretion; AT, adrenal tumor; BMI, body mass index; ACTH, adrenocorticotropic hormone; DST, dexamethasone suppression test; DHEAS, dehydroepiandrosterone sulfate; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; TRACP-5b, tartrate-resistant acid phosphatase-5b; BAP, bone-alkaline phosphatase; BMD, bone mineral density; TBS, trabecular bone score; baPWV, brachial-ankle pulse wave velocity.

p < 0.05 was considered significant.

negatively correlated with baPWV (n = 82, r = –0.33; p = 0.002; Fig. 2A). In contrast, BMD at the lumbar spine (n = 88) or femoral neck (n = 93) and baPWV showed no correlation (Fig. 2B and C). BAP and intact-PTH levels were positively correlated with baPWV (n = 85, r = 0.22; p = 0.039 and n = 90, r = 0.27; p = 0.011, respectively; Fig. 2D and F). Further, TRACP-5b level and baPWV showed no correlation (n = 86; Fig. 2E).

3.3. Association between bone and vascular parameters in the patients with ACS after adjusting for possible confounders

We examined the association between vertebral fractures and arterial stiffness in patients with ACS (Table 2). In these analyses, age and BMI were log-transformed. Vertebral fracture was associated with arterial stiffness (n = 76; odds ratio [OR] = 2.74; 95% confidence interval [CI]: 1.06–7.42; p = 0.048). The association remained significant even after adjusting for age, gender, BMI, alcohol intake, smoking status, and the presence of diabetes mellitus in model 1 (OR = 3.29; 95% CI: 1.07–10.9; p = 0.041), but attenuated in models 2 and 3 (diabetes mellitus of model 1 replaced by hypertension and hyperlipidemia, respectively; p = 0.070 and p = 0.076, respectively). Severe vertebral fracture was associated with arterial stiffness (n = 76; p = 0.026), and the association remained significant even after the adjustment in models 1–3 (p < 0.05). In addition, vertebral fracture was associated with abdominal aortic calcification (n = 77; p = 0.026; Supplementary Table 1). The association remained significant even after the adjustment.
in model 1 (p = 0.048), but was attenuated in models 2 and 3 (p = 0.077 and p = 0.063, respectively).

3.4. Comparison of clinical characteristics among patients with CS, SCS, and non-functional AT

We compared the clinical characteristics among the three groups of patients with CS (n = 17), SCS (n = 80), and non-functional AT (n = 97) (Supplementary Table 2). Patients with CS were younger than those with SCS and non-functional AT. Other baseline parameters, such as gender, BMI, alcohol intake, or smoking status, showed no significant difference. The rate of coexistence of vertebral fracture with arterial stiffness and abdominal aortic calcification showed an association among the three groups (p < 0.001 for both).

3.5. Cortisol excess as a determinant of the correlation between bone and vascular parameters

The MANOVA was performed to evaluate whether an excess of cortisol determined the correlation between bone and vascular parameters (Table 3). In these analyses, the TBS, BMD, BAP level, TRACP5b level, intact-PTH level, and baPWV were log-transformed. *, p < 0.05 was considered significant.

Fig. 2. Correlation between bone and vascular parameters in patients with ACS.
(A) TBS was negatively correlated with baPWV (n = 82). (B, C) There were no correlations between BMD at lumbar spine and femoral neck and baPWV (n = 88 and n = 93, respectively) (D, F) BAP and intact-PTH levels were positively correlated with baPWV (n = 85 and n = 90, respectively). (E) There was no correlation between TRACP5b levels and baPWV (n = 86). In these analyses, the TBS, BMD, BAP level, TRACP5b level, intact-PTH level, and baPWV were log-transformed. *, p < 0.05 was considered significant.

Abbreviations: ACS, autonomous cortisol secretion; baPWV, brachial-ankle pulse wave velocity; TBS, trabecular bone score; BMD, bone mineral density; BAP, bone-alkaline phosphatase, TRACP5b, tartrate-resistant acid phosphatase-5b; PTH, parathyroid hormone.

Table 2
Association between bone and vascular parameters in patients with ACS after adjusting for possible confounders.

| Variables                        | OR   | 95%CI     | p-Value |
|----------------------------------|------|-----------|---------|
| Association between vertebral fracture and arterial stiffness (n = 76) |      |           |         |
| Crude                            | 2.74 | 1.06-7.42 | 0.040   |
| Model 1                          | 3.29 | 1.07-10.9 | 0.041   |
| Model 2                          | 2.94 | 0.93-9.97 | 0.070   |
| Model 3                          | 2.70 | 0.91-8.48 | 0.076   |
| Association between severe vertebral fracture and arterial stiffness (n = 76) |      |           |         |
| Crude                            | 4.40 | 1.23-18.1 | 0.026   |
| Model 1                          | 9.36 | 1.90-63.7 | 0.010   |
| Model 2                          | 6.01 | 1.19-41.2 | 0.041   |
| Model 3                          | 5.33 | 1.26-28.7 | 0.031   |

Arterial stiffness was defined as a baPWV ≥1800 cm/s. Severe vertebral fracture was defined as multiple vertebral fractures or a grade 3 vertebral fracture. In these analyses, age, gender, BMI, alcohol intake, smoking status, and the presence of diabetes mellitus were adjusted in model 1, and diabetes mellitus of model 1 was replaced by hypertension and hyperlipidemia in models 2 and 3, respectively. Age and BMI were log-transformed.

Abbreviations: ACS, autonomous cortisol secretion; baPWV, brachial-ankle pulse wave velocity; OR, odds ratio; CI, confidence interval; BMI, body mass index. * p < 0.05 was considered significant.
alkaline phosphatase; PTH, parathyroid hormone; BMI, body mass index. brachial-ankle pulse wave velocity; TBS, trabecular bone score; BAP, bone-syndrome; SCS, subclinical Cushing’s syndrome; AT, adrenal tumor; baPWV, level, baPWV, age, and BMI were log-transformed.

In these analyses, the degree of cortisol excess (defined as CS, SCS, and non-functional AT) was the independent variable. Age, gender, BMI, alcohol intake, smoking status, and the presence of diabetes mellitus were adjusted in model 1, and diabetes mellitus of model 1 was replaced by hypertension and hyperlipidemia in models 2 and 3, respectively. The TBS, BAP, intact-PTH level, baPWV, age, and BMI were log-transformed.

Abbreviations: MANOVA, multivariate analysis of variance; Num df, numerator degrees of freedom; Den df, denominator degrees of freedom; CS, overt Cushing’s syndrome; SCS, subclinical Cushing’s syndrome; AT, adrenal tumor; baPWV, brachial-ankle pulse wave velocity; TBS, trabecular bone score; BAP, bone-alkaline phosphatase; PTH, parathyroid hormone; BMI, body mass index.

\[ p < 0.05 \] was considered significant.

diabetes mellitus in model 1 was replaced by hypertension and hyperlipidemia in models 2 and 3, respectively. The degree of cortisol excess determined the correlation between BAP level and baPWV (n = 177; p < 0.001; partial \( \eta^2 = 0.05 \)), and between intact-PTH level and baPWV (n = 184; p = 0.006; partial \( \eta^2 = 0.04 \)), after the adjustment in model 1. Similar results were obtained in models 2 and 3.

### 3.6. Differences in post-DST cortisol between patients with and without coexisting bone and subclinical vascular diseases

The ANCOVA was performed to compare post-DST cortisol between patients with and without coexisting vertebral fracture and arterial stiffness. In these analyses, the post-DST cortisol, age, and BMI were log-transformed. Patients with both vertebral fracture and arterial stiffness (n = 20) had higher levels of post-DST cortisol than those without (n = 139) after adjusting for age, gender, BMI, alcohol intake, smoking status, and the presence of diabetes mellitus in model 1 (least-squares mean [95 % CI]: 1.72 [1.49–1.94] vs. 0.70 [0.60–0.79]; p < 0.001; Fig. 3A).

The results were similar when diabetes mellitus in model 1 was replaced by hypertension and hyperlipidemia in models 2 and 3, respectively (Fig. 3B and C). In models 1–3, patients with coexisting vertebral fracture and abdominal aortic calcification had higher levels of post-DST cortisol than those without this coexistence (n = 18 and 143, respectively) (Supplementary Fig. 1A-1C).

In addition, we adjusted simultaneously for the 3 variables of the presence of diabetes mellitus, hypertension, and hyperlipidemia, with results similar to those obtained when adjusted individually. Patients with both vertebral fracture and arterial stiffness had higher levels of post-DST cortisol than those without after adjusting for age, gender, BMI, alcohol intake, smoking status, the presence of diabetes mellitus, hypertension, and hyperlipidemia (least-squares mean [95 % CI]: 1.48 [1.24–1.73] vs. 0.63 [0.54–0.72]; p = 0.005) (Supplementary Fig. 2A).

Similar results were obtained when comparing patients with both vertebral fractures and abdominal aortic calcification with those without (least-squares mean [95 % CI]: 1.44 [1.19–1.69] vs. 0.67 [0.58–0.76]; p = 0.001) (Supplementary Fig. 2B).

### 4. Discussion

This study demonstrated that patients with endogenous glucocorticoid excess frequently developed coexisting vertebral fracture and arterial stiffness, or vertebral fracture and abdominal aortic calcification. Further, endogenous glucocorticoid excess was associated with each of bone and vascular disease, which was consistent with previous reports (Hermus et al., 1995; Tauchmanová et al., 2006; Chioldi et al., 2009; van Haalen et al., 2015; Faggiano et al., 2003; Neary et al., 2013).

Patients with both vertebral fractures and arterial stiffness showed higher levels of post-DST cortisol than those without these conditions, irrespective of the dysmetabolic state. Previous clinical studies addressed the association of endogenous glucocorticoid excess with bone or vascular disease; however, both bone and vascular diseases were not investigated together. These observations suggested that excess endogenous cortisol leads to the progression of bone and subclinical vascular diseases simultaneously. Considering that exogenous glucocorticoid excess can be confounded by the primary disease, our findings obtained in patients with endogenous CS support the notion that glucocorticoid excess perturbs the bone-vascular axis.

In vitro evidence suggests that a possible mechanism through which glucocorticoid excess perturbs the bone-vascular axis is that glucocorticoid administration increases alkaline phosphatase activity and calcification (i.e., osteogenic differentiation) in vascular smooth muscle cells and vascular pericytes (Kirton et al., 2006; Mori et al., 1999). In this study, we found that endogenous glucocorticoid excess determined the positive correlation between the BAP level and baPWV, suggesting that the BAP level reflects osteogenic differentiation of vascular cells and the development of vascular disease. Furthermore, we need to consider not only the direct effects of glucocorticoid excess on bone and vascular diseases, but also the indirect effects via PTH. Glucocorticoid excess is known to cause secondary hyperparathyroidism (Hardy et al., 2018), as patients with ACS had elevated levels of urinary calcium excretion and serum intact-PTH in this study. PTH is an important regulator of bone and vascular disease; continuous exposure to PTH promotes bone remodeling, resulting in skeletal catabolism (Silva and Bilezikian, 2015). It also promotes vascular calcification and remodeling (Bernardi et al., 2021). In this study, glucocorticoid excess determined a positive correlation of the intact-PTH level with baPWV, suggesting that the effect of glucocorticoid excess on the bone-vascular axis is partially mediated by PTH action.

In patients with endogenous cortisol excess, TBS and baPWV showed a negative correlation, but BMD and baPWV showed no correlation, suggesting that deteriorated bone quality, and not decreased bone mass, was related to arterial stiffness. Glucocorticoid excess could have a greater influence on the bone microarchitecture than that on areal BMD (Dalle Carbonare et al., 2001). Further, TBS is an independent predictor of fractures in glucocorticoid-induced osteoporosis (Florez et al., 2020).

Thus, our results may be explained in part by the notion that bone quality, and not bone mass, underlies the pathology of glucocorticoid-induced osteoporosis. Further studies are required to address whether or not oxidative stress, a major determinant of bone deterioration and atherosclerosis, mediates coexisting bone and vascular diseases in patients with endogenous glucocorticoid excess (Saito et al., 2014; Kattoor et al., 2017).

This study has clinical implications for the management of patients with excess glucocorticoids. Particularly, patients with arterial stiffness may have deteriorated bone quality, even without decreased bone mass. For patients with endogenous glucocorticoid excess in this study, arterial stiffness was an independent risk factor for severe vertebral fractures, which is a risk factor for future fractures (Kanis, 2002). For patients with glucocorticoid excess with arterial stiffness, we suggest the lateral radiographs of the thoracic and lumbar spines to confirm vertebral fracture even when they have normal BMD.
In addition to pathological glucocorticoid excess, mild glucocorticoid excess due to aging and chronic stress may be involved in the development of age-related diseases (van den Beld et al., 2018). Previous experimental studies have suggested that mild glucocorticoid excess with aging accelerates bone and vascular diseases simultaneously (Manolagas, 2010). Considering the increasing unmet clinical needs, such as therapeutic strategies that target common molecular pathways in age-related diseases (Thompson and Towler, 2012; Khosla et al., 2018), factors contributing to coexisting bone and vascular diseases should be investigated. This study provides clues to understand the role of glucocorticoid excess as a critical mediator of the bone-vascular axis.

When extrapolating our results to Cushing’s disease by pituitary adenomas, it is necessary to consider that the pattern of adrenal steroid secretion is different from that of adrenal CS. ACTH-dependent Cushing’s disease promotes steroid synthesis in the zona reticularis as well as in the zona fasciculata of adrenal cortex, and serum DHEAS levels are generally elevated; in contrast, they are often low in adrenal CS. DHEAS is a prohormone for sex hormone synthesis and has protective effects on bone and vascular diseases (Yokomoto-Umakoshi et al., 2021; Zhao et al., 2020). In fact, it has been reported that bone loss is milder in Cushing’s disease than in adrenal CS (Minetto et al., 2004), and thus Cushing’s disease and adrenal CS may have different coexistence rates of bone and vascular disease.

5. Limitations

This study has several limitations. First, it was a single center and retrospective study. Second, the sample size was small. In the logistic regression analysis, there was a tendency for an association between vertebral fracture and arterial stiffness, even after adjusting for possible confounders including the presence of hypertension or hyperlipidemia in patients with ACS, with no statistical significance. This may be partly because of the small sample size. Therefore, a multicenter prospective study should be conducted to validate our findings. Second, future mechanistic studies are needed to investigate the direct effects of glucocorticoid excess on the bone-vascular axis, independent of PTH action. Third, none of the patients in this study were also supplemented with calcium or vitamin D as medical treatment, but we were unable to ascertain whether patients were taking them personally. Fourth, this study was not able to evaluate the intima-media thickness or the coronary calcification score on CT. In addition, baPWV was examined as a part of routine medical care, and thus the reproducibility of the baPWV measurement could not be confirmed. The coefficients of variation of biochemical measurements such as intact-PTH, TRACP-5b, BAP, and 25-hydroxyvitamin D could not be evaluated. We could not even evaluation sclerostin. Osteocyte-derived protein sclerostin is a negative regulator of the Wnt/β-catenin signaling and is reported to prevent vascular calcification (De Maré et al., 2022). Glucocorticoid excess is associated with decreased circulating sclerostin levels in humans, suggesting that this...
may be due to decreased osteocyte number or function (van Lierop et al., 2012). Thus, sclerostin may be involved in the effects of glucocorticoid excess on bone-vascular axis. Furthermore, due to the small sample size of this study, it was not possible to simultaneously adjusting for the presence of diabetes, hypertension, and hyperlipidemia in the logistic regression analysis to examine the association between vertebral fractures and arterial stiffness. Finally, the selection of control patients could be a limitation, since a recent study reported that patients with non-functional AT are at an increased risk of cardiometabolic diseases (van Lierop et al., 2016); hence, the control patients with non-functional AT may have a higher risk of bone and vascular diseases than the general population, which may underestimate the risks in patients with ACS.

6. Conclusion

In endogenous glucocorticoid excess, bone and vascular diseases frequently coexisted, and deteriorated bone quality, not bone loss, was related to arterial stiffness. This study may contribute to the appropriate management of such patients and provide new insights into our understanding of the bone-vascular axis.

Data availability

Data supporting the findings presented in this study are available from the corresponding authors upon reasonable request.

Funding

This work was supported in part by the grants from “JSPS KAKENHI” (JP20K16525 and 21J40043 to M.-Y.U., 22H04993 to Y.O., and 22K08627 to H.U.), “The JSBMR Rising Stars Grant” (to M.-Y.U.), “JAPAN Osteoporosis Foundation” (to M.-Y.U.), “Takeda Science Foundation” (to H.U.), “Kaibara Morikazu Medical Science Promotion Foundation” (to H.U. and M.-Y.U.), “Japan Foundation for Applied Enzymology” (to H.U. and M.-Y.U.), “The Uehara Memorial Foundation” (to H.U.), and “Secom Science and Technology Foundation” (to Y.O.).

CRediT authorship contribution statement

Conceptualization; CY, MY-U, YO, Data curation; CY, RS, YM, SK, NI, Formal analysis; CY, MY-U, MF, MO, TF, Funding acquisition; MY-U, HY, YO, Methodology; HY, MY-U, YO, Project administration; HY, YM, MY-U, YO, Resources; YM, RS, MY-U, Supervision; HU, NI, RS, ET, YO, Writing-original draft; CY, MY-U, Writing-review & editing; CY, MY-U, HY, SY, YO.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank Ms. Chitose Matsuzaki (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University), and Ms. Tomoko Kimura and Ms. Noriko Mizoguchi (Division of Radiology, Department of Medical Technology, Kyushu University Hospital) for their technical assistance, and the medical staff of Department of Endocrinology, Metabolism, and Diabetes, Kyushu University Hospital for their support. We also thank Editage (www.editage.com) for English language editing. MY-U is grateful for the JSPS Research Fellowship RPD.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bonr.2022.101610.

References

Baggery, Y.Z., Tankoi, L.B., Alexanderson, P., Qin, G., Christiansen, C., 2006. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med. 259 (6), 598-605.
van den Beld, A.W., Kaufman, J.M., Zillikens, M.C., et al., 2018. The physiology of aging. Lancet Diabetes Endocrinology 6 (8), 647-658.
Bernardi, S., Giudici, F., Barbata, V., et al., 2021. Meta-analysis on the effect of mild primary hyperparathyroidism and parathyroidectomy upon arterial stiffness. J. Clin. Endocrinol. Metab. 106 (6), 1832-1843.
Chiodini, I., Morelli, V., Manzerini, B., et al., 2009. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 94 (9), 3207-3214.
Dalle Carbonare, L., Arlt, M.E., Chavassieux, P.M., et al., 2001. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16 (1), 97-103.
De Marti, A., Opdebeeck, B., Neven, E., D’Haese, P.C., Verbist, A., 2022. Sclerostin protects against vascular calcification development in mice. J. Bone Miner. Res. 37 (4), 687-699.
Ensrud, K.E., Crandall, C.J., 2017. Osteoporosis. Ann. Intern. Med. 167, ITC17-32.
Faggiano, A., Pinovello, R., Spiezia, S., et al., 2003. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88 (6), 2527-2533.
Fassnacht, M., Arlt, W., Bancos, I., et al., 2016. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175 (2), G1-G34.
Florez, H., Hernandez-Rodriguez, J., Muni, A., et al., 2020. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology (Oxford) (59) (7), 1574-1580.
Genant, H.K., Wu, C.Y., van Kuijk, C., et al., 1993. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8, 1137-1146.
van Haalen, F.M., Broersen, L.H., Jorgensen, J.O., Pereira, A.M., Dekkers, O.M., 2015. Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur. J. Endocrinol. 172 (4), R143-R149.
Hardy, R.S., Zhou, H., Seibel, M.J., Cooper, M.S., 2018. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr. Rev. 39 (5), 519-548.
Hermus, A.R., Smals, A.G., Swinkels, L.M., et al., 1995. Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 80 (10), 2859-2865.
Herrington, W., Lacey, B., Sherfiker, P., Armitage, J., Lewington, S., 2016. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ. Res. 118 (4), 535-546.
Kanis, J.A., 2002. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929-1936.
Kattoor, A.I., Pothineni, N.V.K., Palagiri, D., Mehta, J.L., 2017. Oxidative stress in atherosclerosis. Curr. Atheroscler. Rep. 19 (11), 42.
Knappila, L.I., Polak, J.F., Cupples, L.A., Hannan, M.T., Kiel, D.P., et al., 1997. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132, 245-256.
Kholsa, S., Farr, J.N., Kirkland, J.L., 2018. Inhibiting cellular senescence: a new therapeutic paradigm for age-related osteoporosis. J. Clin. Endocrinol. Metab. 103 (4), 1282-1290.
Kirton, J.P., Wilkinson, F.L., Canfield, A.E., Alexander, M.Y., 2006. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ. Res. 98 (10), 1264-1272.
Lewis, J.R., Eggemont, C.J., Schoubroeck, J.T., et al., 2019. Association between abdominal aortic calcification, bone mineral density, and fracture in older women. J. Bone Miner. Res. 34 (11), 2052-2060.
van Lierop, A.H., van der Eerden, A.W., Hamdy, N.A., Hermus, A.R., den Heijer, M., Pappadopulos, S.E., 2012. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J. Clin. Endocrinol. Metab. 97 (10), E1953-E1957.
Lopez, D., Luque-Fernandez, M.A., Steele, A., et al., 2016. "Nonfunctional" adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann. Intern. Med. 165 (8), 533-542.
Manolagas, S.C., 2010. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31 (3), 266-300.
Minetto, M., Reimondo, G., Osella, G., Ventura, M., Angeli, A., Terzolo, M., 2004. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing’s syndrome. Osteoporos. Int. 15 (11), 855-861.
Mori, H.K., Shioi, A., Jono, S., Nishizawa, Y., Mori, H., 1999. Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19 (9), 2112-2118.
Munakata, M., 2014. Brachial-ankle pulse wave velocity in the measurement of arterial stiffness: recent evidence and clinical applications. Curr. Hypertens. Rev. 10 (1), 49-57.

Neary, N.M., Booker, O.J., Abel, B.S., et al., 2013. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J. Clin. Endocrinol. Metab. 98 (5), 2045-2052.

Newell-Price, J., Bertagna, X., Grossman, A.B., Nieman, L.K., 2006. Cushing’s syndrome. Lancet 367 (9522), 1605-1617.

Nieman, L.K., Biller, B.M., Findling, J.W., et al., 2008. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526-1540.

R Core Team, 2013. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

Raisi-Estabragh, Z., Biasiolli, L., Cooper, J., et al., 2021. Poor bone quality is associated with greater arterial stiffness: insights from the UK biobank. J. Bone Miner. Res. 36 (1), 90-99.

Saito, M., Kida, Y., Kato, S., Marumo, K., 2014. Diabetes, collagen, and bone quality. Curr. Osteoporos. Rep. 12 (2), 181–188.

Silva, B.C., Bilezikian, J.P., 2015. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr. Opin. Pharmacol. 22, 41-50.

Soen, S., Fukunaga, M., Sugimoto, T., et al., 2013. Diagnostic criteria for primary osteoporosis: year 2012 revision. J. Bone Miner. Metab. 31 (3), 247–257.

Szulc, P., 2016. Abdominal aortic calcification: a reappraisal of epidemiological and pathophysiological data. Bone 84, 25–37.

Tanko, L.B., Christiansen, C., Cox, D.A., et al., 2005. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone Miner. Res. 20 (11), 1912-1920.

Tauchmanova, L., Pivonello, R., Di Somma, C., et al., 2006. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J. Clin. Endocrinol. Metab. 91 (5), 1779-1784.

Thompson, B., Towler, D.A., 2012. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat. Rev. Endocrinol. 8 (9), 529-543.

Toth, M., Grossman, A., 2013. Glucocorticoid-induced osteoporosis: lessons from Cushing’s syndrome. Clin. Endocrinol. 79 (1), 1-11.

Townsend, R.R., Wilkinson, L.B., Schiffin, E.L., et al., 2015. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension 66 (3), 698-722.

Wagenknecht, L.E., Divers, J., Register, T.C., et al., 2016. Bone mineral density and progression of subclinical atherosclerosis in African-Americans with type 2 diabetes. J. Clin. Endocrinol. Metab. 101 (11), 4135-4141.

Yokomoto-Umakoshi, M., Umakoshi, H., Fujimoto, T., et al., 2020. Pheochromocytoma and paraganglioma: an emerging cause of secondary osteoporosis. Bone 115221.

Yokomoto-Umakoshi, M., Umakoshi, H., Ogata, M., et al., 2020. Coexistence of osteoporosis and atherosclerosis in pheochromocytoma: new insights into its long-term management. Osteoporos. Int. 31 (11), 2151-2160.

Yokomoto-Umakoshi, M., Sakamoto, R., Umakoshi, H., et al., 2020. Unilateral primary aldosteronism as an independent risk factor for vertebral fracture. Clin. Endocrinol. 92 (3), 206-213.

Yokomoto-Umakoshi, M., Umakoshi, H., Iwahashi, N., Matsuda, Y., Kaneko, H., Ogata, M., Fujimoto, T., Terada, E., Nakano, Y., Sakamoto, R., Ogawa, Y., 2021. Protective role of DHEAS in age-related changes in bone mass and fracture risk. J. Clin. Endocrinol. Metab. 106 (11), e4580-e4592.

Zhao, D., Guallar, E., Ballantyne, C.M., Post, W.S., Ouyang, P., Vaidya, D., Jia, X., Ying, W., Subramanya, V., Nduame, C.E., Hoogeveen, R.C., Michos, E.D., 2020. Sex hormones and incident heart failure in men and postmenopausal women: the atherosclerosis risk in communities study. J. Clin. Endocrinol. Metab. 105 (10), e3798-e3807.